Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.

Stephen W ReeseEugene ConeMaya MarcheseBrenda GarciaWesley ChouAsha AyubKerry KilbridgeGerald WeinhouseQuoc Dien Trinh

Published in: Lung (2021)

Immune checkpoint inhibitors are associated with a spectrum of inflammatory pulmonary toxicities. The breadth of pulmonary complications and prevalence may be underappreciated with the use of these agents.

Keyphrases

pulmonary hypertension
risk factors
emergency department
drug induced
bone marrow
cell therapy